Última alteração: 2021-02-25
Resumo
Referências
1. Barré-Sinoussi F, Ross AL, Delfraissy J-F. Past, present and future: 30 years of HIV research. Nature Reviews Microbiology. 2013 Dec 28;11(12):877–83.
2. Ministério da Saúde. Boletim Epidemiologico HIV Aids 2017. HIV Aids Boletim Epidemiológico. 2017.
3. Yoshimura K. Current status of HIV/AIDS in the ART era. Journal of Infection and Chemotherapy. 2017 Jan;23(1):12–6.
4. Soliman M, Srikrishna G, Balagopal A. Mechanisms of HIV-1 Control. Current HIV/AIDS Reports. 2017 Jun 2;14(3):101–9.
5. Diaz RS, Inocêncio LA, Sucupira MCA, Pereira AA, Hunter J, Ferreira JE, et al. The Virological and Immunological Characteristics of the HIV-1-Infected Population in Brazil: From Initial Diagnosis to Impact of Antiretroviral Use. PloS one. 2015;10(10):e0139677.
6. Stadeli KM, Richman DD. Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review. Antiviral Therapy. 2012;18(1):115–23.
7. WHO | HIV drug resistance report 2017. WHO. 2017;
8. WHO. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV: interim guidance. WHO. World Health Organization; 2018.
9. Brasil. Ministério da Saúde. Departamento de Vigilância, Prevenção e Controle das Infecções Sexualmente Transmissíveis do H e das HV. Protocolo Clínico e Diretrizes Terapêuticas para Manejo da Infecção pelo HIV em Adultos. Brasilia: Ministério da Saúde; 2018. 93–102 p.
10. Shafer RW. Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clinical microbiology reviews. 2002 Apr;15(2):247–77.
11. Clutter DS, Jordan MR, Bertagnolio S, Shafer RW. HIV-1 drug resistance and resistance testing. Infection, Genetics and Evolution. 2016 Dec;46:292–307.
12. Tang MW, Shafer RW. HIV-1 Antiretroviral Resistance. Drugs. 2012 Jun;72(9):e1–25.
13. Kandel CE, Walmsley SL. Dolutegravir – A review of the pharmacology, efficacy, and safety in the treatment of HIV. Drug Design, Development and Therapy. 2015.
14. Beyrer C, Pozniak A. HIV Drug Resistance — An Emerging Threat to Epidemic Control. New England Journal of Medicine. 2017 Oct 26;377(17):1605–7.
15. Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. Arch Intern Med. 1998 Sep 14;158(16):1789–95.
16. Gomes-Oliveira MH, Gorenstein C, Neto FL, Andrade LH, Wang YP. Validation of the Brazilian Portuguese Version of the Beck Depression Inventory-II in a community sample. Revista Brasileira de Psiquiatria. 2012 Dec;34(4):389–94.